Importantly, the PIK3CA in case 6 and NRAS in case 1 and 3 are rational candidates for off-label targeted treatments and the NOTCH1 mutation in case 1 is eligible for inclusion in an ongoing clinical trial for advanced salivary gland cancers (clinicaltrials.gov identifier: NCT020697309) (Table 3). This evidence concerns the gene NRAS and salivary gland cancer.